Form 4: Baxter International EVP Reazur Rasul Reports Acquisition and Disposal of Common Stock

Reazur Rasul, EVP at Baxter International, reports the acquisition of 83,353 shares of common stock and disposal of 109,187 shares.

Summary

• On March 6, 2024, Reazur Rasul, an EVP at Baxter International Inc., reported acquiring 83,353 shares of common stock at $0 and disposing of 109,187 shares.
• Following these transactions, Rasul directly owns 109,187 shares of Baxter International Inc.
• The acquisition of shares was related to the annual equity grant for 2024, consisting solely of restricted stock units (RSUs).
• The RSUs are scheduled to vest in three equal annual installments beginning on March 6, 2025, subject to vesting requirements in the Baxter International Inc. 2021 Incentive Plan.
• Rasul has granted power of attorney to David S. Rosenbloom, Ellen K. Bradford, and Kimberly Olson to execute Forms 4, 5, and 144 on his behalf.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions by an executive. The acquisition of shares is generally positive, but the disposal tempers the overall sentiment.

Positives

• The acquisition of shares indicates continued alignment of the executive's interests with those of the shareholders.

Negatives

• The disposal of 109,187 shares could be interpreted negatively, although the context of the transaction (related to equity grants and vesting) needs to be considered.

Risks

• The vesting of RSUs is subject to the executive's continued employment and the terms of the Baxter International Inc. 2021 Incentive Plan.
• Significant disposal of shares by executives could negatively impact investor sentiment.

Future Outlook

The document outlines the vesting schedule for the RSUs, with the first installment vesting on March 6, 2025, subject to continued employment and plan terms.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates routine equity compensation activity.

Comparison to Industry Standards

• Equity compensation is a common practice among publicly traded companies to align executive interests with shareholder value.
• Vesting schedules, like the three-year annual installment plan described, are typical in RSU grants.
• Comparing the size of the equity grant to those of executives at peer companies (e.g., Medtronic, Johnson & Johnson) would provide further context on the competitiveness of Baxter's compensation practices.

Stakeholder Impact

• Shareholders may view the equity grant as a positive sign of aligning management interests with company performance.
• Employees may see the executive's stock ownership as a reflection of confidence in the company's future.

Next Steps

• Monitor future Form 4 filings by Reazur Rasul and other Baxter International executives for further insights into their stock ownership and trading activity.
• Track the vesting of the RSUs on March 6, 2025, and subsequent vesting dates.

Key Dates